Drug Trial Radar · NCT06372652
A Phase 1 Study of TE-8214 Solution in Healthy Volunteers
Last checked: Nov 20, 2026Latest source record: May 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Jun 18, 2024
Primary completion
Oct 10, 2024
Study completion Dec 6, 2024
Sponsor
- Lead sponsor
- Immunwork, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1, first-in-human, randomized, double-blinded, placebo-controlled study to evaluate the safety, tolerability, and PK of TE-8214 in healthy volunteers. The study will assess single ascending doses (SAD) of TE-8214.
Conditions
- Acromegaly
Interventions
TE-8214 - SADDrug
Cohort 1 - Single subcutaneous dose of 0.6 mg Cohort 2- Single subcutaneous dose of 1.2 mg Cohort 3 - Single subcutaneous dose of 2.0 mg Cohort 4 - Single subcutaneous dose of 3.0 mg or 4.0 mg Cohort 5 (Optional) - Single subcutaneous dose of 6.0 mg
PlaceboDrug
Single subcutaneous dose of matching placebo across the cohorts
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of TE-8214 by the incidence of treatment-emergent adverse events (TEAEs)Time frame: From administration of IP on Day 1 until the EOS/ET visit (Day 84) post dose
- Safety and tolerability of TE-8214 by the incidence of treatment-related adverse eventsTime frame: From screening until the EOS/ET visit (Day 84) post dose
- Safety and tolerability of TE-8214 by the incidence of injection site reactions (ISRs)Time frame: On Day 1, 0 hour, 6 hours, 12 hours, 24 hours, 48 hours,72 hours, 96 hours, 168 hours post dose
- Safety and tolerability of TE-8214 by the incidence of clinically significant laboratory findingsTime frame: From Screening until EOS/ET (Day 84) post dose
- Safety and tolerability of TE-8214 by the changes in physical examination findingsTime frame: At Screening, Day -1, Day 2, Day 8, Day 28, Day 56, Day 84 post dose
- Safety and tolerability of TE-8214 by the changes in ECG findingsTime frame: At Screening, Day -1, Day 1, Day 2, Day 4, Day 8, Day 14, Day 28, Day 56, Day 84 post dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CMAX Clinical Research
Adelaide, South Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.